Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Withdrawal symptoms

Neuromed Pharmaceuticals Ltd. believes it has a trial design for Oros hydromorphone that will lead to success after Johnson & Johnson dropped efforts to win FDA approval. Investors last week ponied up $53.3 million in a series E round to back that up. The funds will help finance the company's Phase III program in chronic pain, after which revenues from an approved drug would

Read the full 642 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers